Inogen has unveiled plans for an IPO worth as much as $86.2 million, becoming one of the few medical device companies to make such a move this year.
Oxford Immunotec Global's Nasdaq debut is relatively modest, though initial trading appeared to boost the price. The developer of a tuberculosis blood test priced its initial shares below range, a sign that the fall surge of diagnostics and medical device IPOs may have peaked.
CardioDx was among the cluster of diagnostics and med tech companies that joined a march to the public markets earlier this fall. But executives have now decided to delay the company's IPO, according to various media reports, citing poor market conditions.
Biocept Laboratories released some details of its IPO plan, and the California cancer diagnostic maker's turn at the public markets remains a modest one.
AutoGenomics has officially pulled back from a proposed IPO filed more than a year ago, adding a downbeat note to an otherwise promising fall during which some diagnostics companies are jumping full-on into the public markets.
Diagnostics outfit CardioDx upped the high end of its planned IPO to $92 million and revealed some details about its envisioned offering.
A month after filing IPO plans, molecular diagnostics test maker Veracyte finally went public on Oct. 30. The South San Francisco company said it sold 5 million shares of common stock for $13 each and pulled in $65 million.
Molecular diagnostics company Veracyte pulled the trigger and finally hit the public markets on Oct. 30, and the South San Francisco company's stock experienced some slight first-day gains. It closed at $13.25, up nearly 2%.
Veracyte disclosed more details about its planned initial public offering and also upped the stakes, raising the proposed maximum from just under $75 million to over $81 million. Separately, the molecular diagnostics maker and 2013 Fierce 15 winner touted positive preliminary results from a trial that would expand the use of its thyroid cancer gene expression test.
Oxford Immunotec Global this week became latest diagnostics company to catch IPO fever. The U.K./U.S. developer of blood tests for tuberculosis announced plans to debut on the public markets in an offering that could raise more than $86 million.